Introduction: Current evidence regarding the clinical outcomes of non-vitamin K oral
anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation (AF) and previous …

Several observational studies have compared the effectiveness and safety outcomes
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …

Background Patients with atrial fibrillation (AF) require oral anticoagulation to prevent
ischemic stroke. However, oral anticoagulation may cause bleeding, and patients with AF …

Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Background and purpose In addition to lowering stroke risk, warfarin use is also associated
with reduced stroke severity in patients with atrial fibrillation and acute ischaemic stroke. It …

Background and Purpose—Warfarin is associated with a better net clinical benefit compared
with no treatment in patients with nonvalvular atrial fibrillation (AF) and history of intracranial …

Background Atrial fibrillation (AF) patients with prior hemorrhagic stroke were excluded from
randomized trials comparing non-vitamin K antagonist oral anticoagulants (NOAC) with …

Background and Purpose—To assess whether the combined analysis of all phase III trials of
nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …